https://www.prnewswire.com/news-releases/lilly-to-present-new-data-at-aan-2019-on-emgality-galcanezumab-gnlm-and-lasmiditan-reinforcing-breadth-of-headache-disorders-portfolio-300842385.html
Emgality
Lilly Receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
https://www.biospace.com/article/releases/lilly-receives-fda-priority-review-designation-for-emgality-galcanezumab-gnlm-injection-for-the-preventive-treatment-of-episodic-cluster-headache-in-adults/
